Able Innovations Works to Transform Frontline Healthcare with USD $6MM in Funding

Able Innovations, a Toronto-based robotic medical device start-up, is garnering significant support for its revolutionary ALTA Platform™ with an announcement of a total raise of USD $6MM.

This represents previously unannounced venture capital and grant funding, including USD $2.5MM in non-dilutive funding.

Able Innovations is using robotics to transform processes for healthcare staff by incorporating safety and dignity into a routine procedure that affects providers and patients.

The ALTA Platform automates the demanding task of patient transfer: moving a patient from one surface to another — e.g.: from bed to stretcher. Such transfers occur frequently and require 2 or more staff to exert back-breaking effort. In a post-pandemic system that is seeing nurses burn out and facilities short-staffed, ALTA enables workers to do more with less.

Able Innovations’ founders Jayiesh Singh and Philip Chang began developing ALTA in 2018, drawing from Jay’s experience volunteering in long-term care, and Philip’s struggles with transfer as a patient himself.

“The intense effort required in patient transfer under the current standard of care is not sustainable,” says Able CEO Jayiesh Singh. “The pandemic has widened cracks in the healthcare system, and patient transfer is one of them.”

Able’s unique solution has resulted in partnerships with leading Canadian and American systems including the U.S. Veterans Health Administration (VHA), Toronto’s University Health Network (UHN), and Ottawa’s Élisabeth Bruyère Hospital.

“Able is redefining values related to patient transfers,” says Dr. Gaurav Puri, Chief of Emergency at Southlake Regional Hospital. “Able has demonstrated its commitment to a device that transfers patients safely, efficiently, and with dignity, while minimizing injuries to staff.”

Able Innovations gratefully acknowledges support of crucial investors and funders including:

Champion physicians Dr. Gaurav Puri and Dr. Andrew Vellathottam
NorthSpring Capital Partners
University of Waterloo’s incubator, Velocity, and its Health Tech Fund
Ontario Centre of Innovation’s Market Readiness Fund
Federal and provincial government grants

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version